Tech

Biotech company Eyestem’s valuation surges 70% in Series B round

Published

on

[ad_1]

Clinical-stage biotech company Eyestem Research recently secured $10 million in a Series B round led by Prabhavati Agro Green Energies with the participation of Jacesa Investments, BNS Capital, Alkem Labs, among others.

The Bengaluru-based company did not disclose key details such as its post-money valuation and shareholding structure in its announcement. Entrackr has sifted through the regulatory filings to uncover the critical details.

The board at Eyestem has issued 45,502 Series B compulsory convertible preference shares at an issue price of Rs…

[ad_2]

Source link

Exit mobile version